PVR and glioblastoma: Here we show, through bioinformatics analyses of transcriptional patient data, in vivo efficacy and survival analysis, as well as pharmacological blockade assays, that targeting of CD155/TIGIT and CD73 carries substantial anti-GBM potential, with dramatic preclinical responses.